BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Hooff J, Van der Walt I, Kallmeyer J, Miller D, Dawood S, Moosa MR, Christiaans M, Karpf C, Undre N. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit. 2012;34:46-52. [PMID: 22249344 DOI: 10.1097/ftd.0b013e318244a7fd] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma TK, Chow KM, Cheng PM, Kwan BC, Leung CB, Li PK, Szeto CC. Pharmacokinetic study of once-daily formulation of tacrolimus (Advagraf) in stable Chinese kidney transplant recipients. Hong Kong Journal of Nephrology 2016;19:1-6. [DOI: 10.1016/j.hkjn.2016.03.002] [Reference Citation Analysis]
2 Lu Z, Bonate P, Keirns J. Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. Br J Clin Pharmacol 2019;85:1692-703. [PMID: 30950096 DOI: 10.1111/bcp.13952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
3 Ho B, Bhagat H, Schwartz JJ, Atiemo K, Daud A, Kang R, Montag SE, Zhao L, Lee E, Skaro AI, Ladner DP. Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization. Adv Ther 2019;36:1465-79. [PMID: 30941724 DOI: 10.1007/s12325-019-00904-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
5 Riegersperger M, Plischke M, Jallitsch-Halper A, Steinhauser C, Födinger M, Winkelmayer WC, Dunkler D, Sunder-Plassmann G. A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes. PLoS One 2019;14:e0218709. [PMID: 31266056 DOI: 10.1371/journal.pone.0218709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Yau WP, Loh CW, Vathsala A. Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. Eur J Drug Metab Pharmacokinet 2019;44:481-92. [PMID: 30471066 DOI: 10.1007/s13318-018-0531-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Tremblay S, Alloway RR. Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. AAPS J 2017;19:1332-47. [PMID: 28717926 DOI: 10.1208/s12248-017-0119-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
8 Undre N, Dickinson J. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. BMJ Open 2017;7:e012252. [PMID: 28377389 DOI: 10.1136/bmjopen-2016-012252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Lapeyraque AL, Kassir N, Théorêt Y, Krajinovic M, Clermont MJ, Litalien C, Phan V. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatr Nephrol 2014;29:1081-8. [PMID: 24435759 DOI: 10.1007/s00467-013-2724-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
10 Sablik KA, Clahsen-van Groningen MC, Hesselink DA, van Gelder T, Betjes MGH. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS One 2018;13:e0196552. [PMID: 29746495 DOI: 10.1371/journal.pone.0196552] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
11 Patel N, Cook A, Greenhalgh E, Rech MA, Rusinak J, Heinrich L. Overview of extended release tacrolimus in solid organ transplantation. World J Transplant 2016; 6(1): 144-154 [PMID: 27011912 DOI: 10.5500/wjt.v6.i1.144] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
12 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
13 van Boekel GA, Donders AR, Hoogtanders KE, Havenith TR, Hilbrands LB, Aarnoutse RE. Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. Eur J Clin Pharmacol 2015;71:811-6. [PMID: 25980838 DOI: 10.1007/s00228-015-1863-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]